Concord Biotech Ltd. (CONCORDBIO) Share Price Rises 5.17% as Mid Cap Stock Enters Top Gainers Today
- August 17, 2026
- Posted by: Harsh Piplani
- Category: News
Concord Biotech Ltd. Share Price Today rose 5.17% to Rs 1,520.9, lifting the mid cap healthcare stock with a market capitalisation of Rs 15,128.55 crore.
Concord Biotech Ltd. Share Price was at Rs 1,520.9 on 17 August 2026 at 3:16:58 PM IST, up Rs 74.8 or 5.17% from the previous close of Rs 1,446.1. With a market capitalisation of Rs 15,128.55 crore, the stock stood out in today’s session as a notable mid cap top gainer within the Healthcare space. For investors tracking Concord Biotech Ltd. Share Price Today, the verified data confirms a strong same-day price rise, a wide intraday range and meaningful participation across BSE and NSE volumes.
What happened today is straightforward: the stock opened at Rs 1,473.5, moved between Rs 1,440.55 and Rs 1,535, and held a sizeable gain into the afternoon. Why is it trending? The supplied data clearly establishes the price event and turnover, but it does not establish a company-specific catalyst behind the move. That makes the session relevant from a market-activity perspective rather than a catalyst-confirmed corporate event.
For readers searching for Concord Biotech Ltd. Stock News, the important points are the current price, the 5.17% share price gain, total traded volume of 5,77,814 shares across exchanges and turnover of Rs 4.25 crore on BSE. Investors should monitor whether Concord Biotech Ltd. Share Price can sustain levels near the day’s upper band, how the Healthcare sector benchmark context shapes relative positioning, and whether the stock’s size advantage versus many listed healthcare peers continues to keep it in focus on Univest and across Stock Market Today screens.
Concord Biotech Ltd. (CONCORDBIO) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,520.9 |
| Previous Close | Rs 1,446.1 |
| Today's Change | +Rs 74.8 (+5.17%) |
| Day Open | Rs 1,473.5 |
| Day High | Rs 1,535 |
| Day Low | Rs 1,440.55 |
| Current Volume (BSE) | 27,974 |
| BSE Traded Volume | 27,974 |
| NSE Traded Volume | 5,49,840 |
| Combined NSE + BSE Volume | 5,77,814 |
| Turnover | Rs 4.25 crore |
| Market Capitalisation | Rs 15,128.55 crore |
| Market Cap Category | Mid Cap |
Concord Biotech Ltd. (CONCORDBIO) traded at Rs 1,520.9. versus the previous close of Rs 1,446.1, a rise of 5.17%. The stock opened at Rs 1,473.5, reached Rs 1,535, touched Rs 1,440.55. Reported volume was 27,974.
Concord Biotech Ltd. (CONCORDBIO) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,128.55 crore |
Concord Biotech Ltd. Share Price is drawing attention today mainly because of price action, but the basic fundamental context still matters. The single most important verified fundamental number supplied here is market capitalisation: Rs 15,128.55 crore. That places Concord Biotech among larger names within the supplied Healthcare benchmark set, even though the stock is categorised as Mid Cap in the event framework. Market capitalisation reflects company size rather than business quality by itself, yet size often influences liquidity, visibility and institutional tracking.
That size gap is also notable against the upper end of the supplied benchmark range. The maximum market capitalisation within the benchmark companies list is Rs 2,985.15 crore, attached to Dishman Carbogen Amcis Ltd. Concord Biotech Ltd. Share Price is therefore attached to a company whose market value is substantially larger than the individual sector comparables listed in the same snapshot. For investors reading Concord Biotech Ltd. Stock News and Concord Biotech Ltd. Share Price Update, that does not automatically say anything about valuation attractiveness, but it does show that the company commands materially greater scale than several healthcare peers shown alongside it.
As a result, today’s fundamental context is less about judging cheapness or expensiveness and more about recognising that Concord Biotech Ltd. Share Price is linked to a sizable healthcare company that sits well above the sector sample’s typical market-cap profile. That makes the next layer of analysis ownership-free but sector-sensitive: how does this stock look against the Healthcare benchmark and listed peers visible in the supplied data?
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Benchmark Median P/E | 26.77x |
| Benchmark Average P/E | 62.82x |
| Benchmark P/E Range | 2.98x to 1,603.4x |
| Benchmark Median P/B | 1.9x |
| Benchmark Median ROE | 10.73% |
| Benchmark Median ROCE | 13.16% |
| Company Market Capitalisation | Rs 15,128.55 crore |
| Benchmark Median Market Cap | Rs 135.27 crore |
Concord Biotech Ltd. (CONCORDBIO) is classified under sector: Healthcare.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
The supplied sector data places Concord Biotech Ltd. Share Price within the Healthcare sector, and that backdrop is important because it frames the stock against a large listed universe rather than in isolation. The benchmark scope is the same sector, and it covers 201 companies. That gives useful context for anyone following Concord Biotech Ltd. Share Price Today, because the move can be read against a broad healthcare market sample.
Within that benchmark, the P/E dataset covers 158 companies, with a median of 26.77, an average of 62.82, a minimum of 2.98 and a maximum of 1,603.4. The P/B sample covers 200 companies, where the median is 1.9 and the average is 2.31, while the range runs from -22.08 to 27.19. Profitability benchmarks also show a wide spread: median ROE is 10.73 and average ROE is 14.57 across 200 companies, while median ROCE is 13.16 and average ROCE is 17.03 across 200 companies.
Market-cap dispersion inside Healthcare is equally striking. The benchmark’s median market capitalisation is Rs 135.27 crore, the average is Rs 456.49 crore, the minimum is Rs 2.19 crore and the maximum is Rs 2,985.15 crore. Against that, Concord Biotech’s market capitalisation of Rs 15,128.55 crore stands out sharply. For Concord Biotech Ltd. Share Price News and sector analysis purposes, this means the company sits far above the benchmark’s central tendency on size, even before looking at peer-level figures.
The sector data also shows how diverse healthcare valuations and returns can be, with extremely wide P/E and P/B ranges. That matters because broad sector averages may not capture the business mix differences between pharmaceuticals, healthcare services and other healthcare subsegments. From a Univest perspective, the clearest verified conclusion is that Concord Biotech Ltd. Share Price is being watched in a sector where valuation and profitability dispersion is high, while the company’s market-cap scale is far above the benchmark median and average.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,985.15 | 184.72 | 0.45 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,827.67 | 68.16 | 6.74 | 18.65 | 22.17 |
| Hikal Ltd. | HIKAL | 2,686.72 | 0 | 2.26 | 15.22 | 16.15 |
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 2,645.37 | 46.15 | 1.77 | -0.78 | 8.31 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,612.26 | 34.27 | 7.07 | -2.6 | 16.92 |
Concord Biotech Ltd. (CONCORDBIO) has a market capitalisation of Rs 15,128.55 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Concord Biotech Ltd. Share Price also looks distinctive when placed beside the supplied peer basket. The listed peers include Dishman Carbogen Amcis Ltd. at Rs 2,985.15 crore market cap, Beta Drugs Ltd. at Rs 2,827.67 crore, Hikal Ltd. at Rs 2,686.72 crore, Ind-Swift Laboratories Ltd. at Rs 2,645.37 crore and Dr Agarwals Eye Hospital Ltd. at Rs 2,612.26 crore. Additional names such as Fredun Pharmaceuticals Ltd., Solara Active Pharma Sciences Ltd., Sai Parenteral’s Ltd., Panacea Biotec Ltd. and Venus Remedies Ltd. all sit in a Rs 2,388.41 crore to Rs 2,559.68 crore band.
Against that group, Concord Biotech’s market capitalisation of Rs 15,128.55 crore is materially larger than every supplied peer. That is the clearest measurable distinction in this peer comparison. Since the dataset does not provide Concord Biotech’s own P/E, P/B, ROE or ROCE, peer analysis here is necessarily centred on scale and on the valuation dispersion visible across comparable healthcare names.
That dispersion is meaningful. Peer P/E values include 184.72 for Dishman Carbogen Amcis, 68.16 for Beta Drugs, 46.15 for Ind-Swift Laboratories, 34.27 for Dr Agarwals Eye Hospital, 58.41 for Fredun Pharmaceuticals, 171 for Sai Parenteral’s and 20.56 for Venus Remedies. P/B ratios also range widely, from 0.45 for Dishman Carbogen Amcis to 8.73 for Fredun Pharmaceuticals. Profitability is mixed as well, with ROE figures from -2.89 to 18.65 and ROCE figures from -0.26 to 22.17 in the supplied set.
For Concord Biotech Ltd. Stock Analysis, the key takeaway is that the stock belongs to a healthcare landscape where peer valuations and returns vary sharply, while the company itself stands apart on market capitalisation. That size premium can increase market visibility, but investors will still need to watch how Concord Biotech Ltd. Share Price behaves relative to this mixed peer backdrop on Univest and in broader Market News flows.
Why Investors Are Watching Concord Biotech Ltd.
Concord Biotech Ltd. Share Price is in focus because today’s move combined a 5.17% gain, a current price of Rs 1,520.9, a session high of Rs 1,535 and total volume of 5,77,814 shares. In a market screen built around Stocks in News and Top Gainers Today, that combination is enough to attract attention even without a verified company-specific trigger in the supplied data.
- Price action: The stock rose Rs 74.8 from Rs 1,446.1 to Rs 1,520.9 after opening at Rs 1,473.5.
- Intraday range: Trading between Rs 1,440.55 and Rs 1,535 shows active price discovery and strong afternoon positioning.
- Volume participation: Total volume reached 5,77,814 shares, with 5,49,840 shares on NSE and 27,974 on BSE.
- Market-cap context: At Rs 15,128.55 crore, the company is far larger than the sector benchmark median and average.
- Sector positioning: Healthcare valuations and profitability benchmarks are widely dispersed, making company-specific tracking important.
What should investors monitor next? The main points are whether Concord Biotech Ltd. Share Price holds near the day’s upper zone, whether follow-through trading keeps it among Market Movers, and how it continues to compare on visibility and scale within Healthcare. Univest users tracking Concord Biotech Ltd. Share Price Live may also watch whether activity remains exchange-broad and whether the stock stays prominent in Stocks Rising Today screens.
About Concord Biotech Ltd.
Concord Biotech Ltd. Share Price is linked in the supplied data to the Healthcare sector. Beyond that sector assignment and the company name, the verified dataset for this article is primarily market-based rather than business-description heavy. That means the most factual company overview is one grounded in how the market currently classifies it and where it sits within the listed healthcare universe.
Within that listed context, Concord Biotech is being tracked as a mid cap healthcare stock with a market capitalisation of Rs 15,128.55 crore. The company is therefore being watched not as a small fringe counter but as a relatively large participant in the sector by market value. The peer and benchmark snapshots used in this article include multiple Healthcare companies spanning pharmaceuticals and healthcare services, showing the breadth of the space in which Concord Biotech Ltd. Share Price is being evaluated.
For readers coming through searches such as Concord Biotech Ltd. Share News, Concord Biotech Ltd. Latest News or Concord Biotech Ltd. Company News, the most reliable immediate takeaway is that the stock currently belongs to a broad, valuation-diverse healthcare ecosystem. In practical terms, that makes ongoing tracking of price action, market capitalisation context, peer positioning and sector benchmark changes especially relevant. Univest readers following Concord Biotech Ltd. Share Price can therefore use the stock’s current move as a starting point for broader healthcare market analysis rather than as a stand-alone headline.
Track Concord Biotech Ltd. Share Price on Univest
Use Concord Biotech Ltd. (CONCORDBIO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors who want to follow Concord Biotech Ltd. Share Price can track it on Univest through live price updates, market capitalisation context, 52-week levels when available, shareholding pattern when available, and broader stock analysis tools. Concord Biotech Ltd. Share Price Today, Concord Biotech Ltd. Stock News and Concord Biotech Ltd. Share Price Update become more useful when viewed alongside sector screens, peer comparison data and market activity trends.
Univest also helps users monitor how a stock appears in Top Gainers Today, Market Movers and sector-specific watchlists. For anyone reviewing Concord Biotech Ltd. Share Price Live, today’s move is a useful example of why combining price action, trading volume and sector context can give a more complete picture than looking at a single percentage change alone.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Concord Biotech Ltd. Share Price today?
Ans. Concord Biotech Ltd. Share Price today was Rs 1,520.9 at 3:16:58 PM IST on 17 August 2026. The stock was up Rs 74.8 from the previous close of Rs 1,446.1, reflecting a 5.17% single-session gain.
Why is Concord Biotech Ltd. Share Price rising today?
Ans. The supplied data confirms that Concord Biotech Ltd. Share Price rose 5.17% today and entered the top-gainer screen. It also shows active trading and a strong intraday range, but the dataset does not identify a company-specific catalyst for the move.
What was the previous close of Concord Biotech Ltd.?
Ans. Concord Biotech Ltd. closed at Rs 1,446.1 in the previous session. Against that base, today’s current price of Rs 1,520.9 represents a gain of Rs 74.8, which translates into a 5.17% rise in the stock price.
What were the day high and day low for Concord Biotech Ltd. Share Price Today?
Ans. Concord Biotech Ltd. Share Price Today traded between a day low of Rs 1,440.55 and a day high of Rs 1,535. The current price of Rs 1,520.9 kept the stock close to the upper end of that intraday range.
How much volume was traded in Concord Biotech Ltd. today?
Ans. Total traded volume in Concord Biotech Ltd. stood at 5,77,814 shares today. Of this, 5,49,840 shares were traded on NSE and 27,974 shares on BSE, showing that participation was much heavier on NSE.
What is the market capitalisation of Concord Biotech Ltd.?
Ans. Concord Biotech Ltd. had a market capitalisation of Rs 15,128.55 crore in the supplied data. That places it well above the Healthcare sector benchmark median of Rs 135.27 crore and average of Rs 456.49 crore.
Is Concord Biotech Ltd. a mid cap stock?
Ans. Yes, the supplied event classification places Concord Biotech Ltd. in the Mid Cap category. That matters because today’s 5.17% share price gain qualified the stock for market-cap-based top-gainer tracking under the event framework.
How does Concord Biotech Ltd. compare with the Healthcare sector on size?
Ans. Concord Biotech Ltd. stands out on size within the supplied Healthcare benchmark. Its market capitalisation is Rs 15,128.55 crore, versus a sector median of Rs 135.27 crore, an average of Rs 456.49 crore and a benchmark maximum of Rs 2,985.15.
Which peers are listed alongside Concord Biotech Ltd. in the comparison set?
Ans. The supplied peer set includes Dishman Carbogen Amcis, Beta Drugs, Hikal, Ind-Swift Laboratories, Dr Agarwals Eye Hospital, Fredun Pharmaceuticals, Solara Active Pharma Sciences, Sai Parenteral's, Panacea Biotec and Venus Remedies across the Healthcare space.
What should investors monitor after today’s Concord Biotech Ltd. Share Price rise?
Ans. Investors can monitor whether Concord Biotech Ltd. Share Price holds near the day’s upper zone, whether volume remains elevated across exchanges, and how the stock continues to compare with Healthcare peers and benchmark size indicators on Univest.
